Patients are randomly assigned to nivolumab plus relatlimab or nivolumab monotherapy, the latter serving as a reference for the evaluation of toxicity, clinical activity and biological impact of dual targeting of PD-1 and LAG-3 in resectable NSCLC. The gene discussed is LAG3; the disease is non-small cell lung carcinoma.